{"id":2721,"date":"2022-04-25T05:30:00","date_gmt":"2022-04-25T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-presents-interim-report-january-march-2022\/"},"modified":"2022-04-25T05:30:00","modified_gmt":"2022-04-25T05:30:00","slug":"xvivo-presents-interim-report-january-march-2022","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/","title":{"rendered":"XVIVO presents interim report January-March 2022"},"content":{"rendered":"
\n

Strong sales growth and key milestones achieved<\/strong><\/p>\n<\/div>\n

\n

First quarter 2022 (1 Jan – 31 Mar)<\/strong>
\u2022 Net sales amounted to SEK 92.7 million (58.3), corresponding to an increase of 59 percent in SEK and 47 percent in local currencies
\u2022 All business areas showed underlying organic growth. Adjusted for currency effects; Thoracic 35 percent, Abdominal 21 percent and Services 53 percent. Acquired growth was 15 percent.
\u2022 Three XPS-machines were sold during the quarter.
\u2022 Gross margin on disposables improved to 79 percent (76). Total gross margin was 70 percent (74) affected by productmix.
\u2022 Operating profit before depreciation and amortization (EBITDA) amounted to SEK 14.7 million (11.2), corresponding to an EBITDA margin of 16 percent (19). Adjusted EBITDA amounted to SEK 15.4 million (6.3), corresponding to an adjusted EBITDA margin of 17 percent (11).
\u2022 Operating profit (EBIT) amounted to SEK 4.6 million (3.2). Adjusted EBIT amounted to SEK 5.3 million (-1.8).
\u2022 Net profit amounted to SEK 4.8 million (6.0). Earnings per share amounted to SEK 0.16 (0.21).
\u2022 Cash flow from operating activities amounted to SEK -9.3 million (10.3), primarily due to payment of employee current liabilities relating to 2021. Total cash flow amounted to SEK -63.6 million (-10.2), effected by payment of final additional purchase price for the acquisition of XVIVO B.V. SEK -21.0 million, and investments in R&D projects SEK -27.1 million.<\/p>\n

Significant events during the quarter<\/strong>
\u2022 XVIVO\u2019s heart technology used in the world\u2019s first ever successful heart xenotransplant (pig to human)
\u2022 Kidney Assist Transport receives 510(k) clearance by US FDA
\u2022 XVIVO obtains its first certificate under EU Medical Device Regulation (MDR) for Kidney Assist Transport
\u2022 Regulatory approval in China for PERFADEX\u00ae<\/sup> Plus obtained<\/p>\n

CEO-comment<\/strong>
\u201cIt was an encouraging start to the year with a new sales record for a single quarter and significant interest in our XPS technology for lungs, which resulted in three sold XPS machines. Due to strong sales and margin improvements in both Thoracic and Abdominal, profitability in the quarter was good. Furthermore, the quarter delivered several key milestones including the xenotransplantation of a heart from a pig to a human, which had extensive media coverage, and the FDA clearance of Kidney Assist Transport in the US – the world\u2019s largest market for kidney transplants.\u201d – Dag Andersson, CEO XVIVO<\/p>\n<\/div>\n

\n

For further information, please contact:<\/strong><\/p>\n\n

Dag Andersson, CEO, +46 76 643 30 31, e-mail:\u00a0dag.andersson@xvivogroup.com
Kristoffer\u00a0Nordstr\u00f6m, CFO, +46 73 519 21 64, e-mail:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n

\n

Conference Call<\/strong><\/p>\n\n

CEO Dag Andersson och CFO Kristoffer Nordstr\u00f6m will present the report in a conference call today at 2 PM CET. Telephone UK: +44\u00a0333\u00a0300 0804, USA: +1\u00a0631\u00a0913 1422\u00a0or\u00a0Sweden:\u00a0+46\u00a08\u00a0566\u00a0426\u00a051 PIN: 20185387#<\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n\n

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com\/us.<\/p>\n<\/div>\n

\n

This information is information that XVIVO Perfusion AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-04-25 07:30 CEST.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n\n

XVIVO Interim Report Jan Mar 2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Strong sales growth and key milestones achieved First quarter 2022 (1 Jan – 31 Mar)\u2022 Net sales amounted to SEK…<\/p>\n","protected":false},"template":"","class_list":["post-2721","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en"],"acf":[],"yoast_head":"\nXVIVO presents interim report January-March 2022 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO presents interim report January-March 2022 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Strong sales growth and key milestones achieved First quarter 2022 (1 Jan – 31 Mar)\u2022 Net sales amounted to SEK...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-march-2022\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-march-2022\\\/\",\"name\":\"XVIVO presents interim report January-March 2022 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2022-04-25T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-march-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-march-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presents-interim-report-january-march-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO presents interim report January-March 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO presents interim report January-March 2022 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO presents interim report January-March 2022 - XVIVO","og_description":"Strong sales growth and key milestones achieved First quarter 2022 (1 Jan – 31 Mar)\u2022 Net sales amounted to SEK...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/","name":"XVIVO presents interim report January-March 2022 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2022-04-25T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presents-interim-report-january-march-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO presents interim report January-March 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}